Inhibition of antibiotic efflux in bacteria by the novel multidrug resistance inhibitors biricodar (VX-710) and timcodar (VX-853)

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 11, 2004, Pages 4171-4176

  Mullin, Steve ^a,b   Mani, Nagraj ^a   Grossman, Trudy H ^a  

^a VERTEX PHARMACEUTICALS   (United States)

^b ActivBiotics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALOID; BIRICODAR; CIPROFLOXACIN; ETHIDIUM BROMIDE; GENTAMICIN; LEVOFLOXACIN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN INHIBITOR; NORFLOXACIN; NOVOBIOCIN; PROTEIN INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RESERPINE; TETRACYCLINE; TETRAPHENYLPHOSPHONIUM; TIMCODAR; UNCLASSIFIED DRUG; VX 853;

ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TRANSPORT; ENTEROCOCCUS FAECALIS; GRAM POSITIVE BACTERIUM; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; BACTERIA; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENTEROCOCCUS FAECALIS; FLUOROQUINOLONES; GENES, MDR; GRAM-POSITIVE BACTERIA; MICROBIAL SENSITIVITY TESTS; P-GLYCOPROTEIN; PIPERIDINES; PYRIDINES; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

EID: 7244260438     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.11.4171-4176.2004     Document Type: Article

References (37)

1. Aeschlimann, J. R., L. D. Dresser, G. W. Kaatz, and M. J. Rybak. 1999. Effects of NorA inhibitors on in vitro antibacterial activities and postantibioitic effects of levofloxacin, ciprofloxacin, and norfloxacin in genetically related strains of Staphylococcus aureus. Antimicrob. Agents Chemother. 43:335-340.
2. Bambeke, F. V., E. Balzi, and P. M. Tulkens. 2000. Antibiotic efflux pumps. Biochem. Pharmacol. 60:457-470.
3. Barrett, J. F. 2001. MC-207110 Daiichi Seiyaku/Microcide Pharmaceuticals. Curr. Opin. Investig. Drugs 2:212-215.
4. Bramwell, V. H. C., D. Morris, D. S. Ernst, I. Hings, M. Blackstein, P. M. Venner, E. I. Ette, M. W. Harding, A. Waxman, and G. D. Demetri. 2002. Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma. Clin. Cancer Res. 8:383-393.
5. Germann, U. A., D. Shlyakhter, V. S. Mason, P. J. Ford, and M. W. Harding. 1996. VX-853: a novel bispecific chemosensitizer which reverses P-glycoprotein- and MRP-dedicated multidrug resistance, abstr. 2283. Proc. 87th Annu. Meet., vol. 37. American Association for Cancer Research, Washington, D.C.
6. Germann, U. A., P. J. Ford, D. Shlyakhter, V. S. Mason, and M. W. Harding. 1997. Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP. Anticancer Drugs 8:141-155.
7. Germann, U. A., D. Shlyakhter, V. S. Mason, R. E. Zelle, J. P. Duffy, V. Galullo, D. M. Armistead, J. O. Saunders, J. Boger, and M. W. Harding. 1997. Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro. Anticancer Drugs 8:125-140.
8. Gibbons, S., M. Oluwatuyi, and G. W. Kaatz. 2003. A novel inhibitor of multidrug efflux pumps in Staphylococcus aureus. J. Antimicrob. Chemother. 51:13-17.
9. Gill, M. J., N. P. Brenwald, and R. Wise. 1999. Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 43:187-189.
10. Kaatz, G. W., V. V. Moudgal, and S. M. Seo. 2002. Identification and characterization of a novel efflux-related multidrug resistance phenotype in Staphylococcus aureus. J. Antimicrob. Chemother. 50:833-838.
11. Kaatz, G. W., V. V. Moudgal, S. M. Seo, and J. E. Kristiansen. 2003. Phenothiazines and thioxanthenes inhibit multidrug efflux pump activity in Staphylococcus aureus. Antimicrob. Agents Chemother. 47:719-726.
12. Kaatz, G. W., and S. M. Seo. 1995. Inducible NorA-mediated multidrug resistance in Staphyolococcus aureus. Antimicrob. Agents Chemother. 39: 2650-2655.
13. Kaatz, G. W., S. M. Seo, and C. A. Ruble. 1993. Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 37:1086-1094.
14. Kohler, T., J. C. Pechere, and P. L. Plesiat. 1999. Bacterial antibiotic efflux systems of medical importance. Cell. Mol. Life Sci. 56:771-778.
15. Koronakis, V., A. Sharff, E. Koronakis, B. Luisi, and C. Hughes. 2000. Crystal structure of the bacterial membrane protein TolC central to multidrug efflux and protein export. Nature 405:914-919.
16. Kuroda, M., T. Ohta, I. Uchiyama, T. Baba, H. Yuzawa, I. Kobayashi, L. Cui, A. Oguchi, K. Aoki, Y. Nagai, J. Lian, T. Ito, M. Kanamori, H. Matsumaru, A. Maruyama, H. Murakami, A. Hosoyama, Y. Mizutani-Ui, N. K. Takahashi, T. Sawano, R. Inoue, C. Kaito, K. Sekimizu, H. Hirakawa, S. Kuhara, S. Goto, J. Yabuzaki, M. Kanehisa, A. Yamashita, K. Oshima, K. Furuya, C. Yoshino, T. Shiba, M. Hattori, N. Ogasawara, H. Hayashi, and K. Hiramatsu. 2001. Whole genome sequencing of methicillin-resistant Staphylococcus aureus. Lancet 357:1225-1240.
17. Lawrence, L. E., and J. F. Barrett. 2000. Inhibition of bacterial efflux: needs, opportunities, and strategies. Curr. Opin. Antiinfect. Investig. Drugs 2:145-153.
18. Lee, E. W., J. Chen, M. N. Huda, T. Kuroda, T. Mizushima, and T. Tsuchiya. 2003. Functional cloning and expression of emeA, and characterization of EmeA, a multidrug efflux pump from Enterococcus faecalis. Biol. Pharm. Bull. 26:266-270.
19. Lomovskaya, O., M. S. Warren, A. Lee, J. Galazzo, R. Fronko, M. Lee, J. Blais, D. Cho, S. Chamberland, T. Renau, R. Leger, S. Hecker, W. Watkins, K. Hoshino, H. Ishida, and V. J. Lee. 2001. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob. Agents Chemother. 45:105-116.
20. Markham, P. N. 1999. Inhibition of the emergence of ciprofloxacin resistance in Streptococcus pneumoniae by the multidrug efflux inhibitor reserpine. Antimicrob. Agents Chemother. 43:988-989.
21. Markham, P. N., and A. A. Neyfakh. 1996. Inhibition of the multidrug transporter NorA prevents emergence of norfloxacin resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 40:2673-2674.
22. Markham, P. N., E. Westhaus, K. Klyachko, M. E. Johnson, and A. A. Neyfakh. 1999. Multiple novel inhibitors of the NorA multidrug transporter of Staphylococcus aureus. Antimicrob. Agents Chemother. 43:2404-2408.
23. Muñoz-Bellido, J. L., M. A. Alonso Manzanares, J. A. Martinez Andrés, M. N. Gutiérrez Zufiaurre, G. Ortiz, M. Segovia Hernández, and J. A. García-Rodríguez. 1999. Efflux pump-mediated quinolone resistance in Staphylococcus aureus strains wild type for gyrA, gyrB, grlA, and norA. Antimicrob. Agents Chemother. 43:354-356.
24. Munoz-Bellido, J. L. M., G. Y. Guirao, N. G. Zufiaurre, and A. A. Manzanares. 2002. Efflux-mediated antibiotic resistance in Gram-positive bacteria. Rev. Med. Microbiol. 13:1-13.
25. Murakami, S., R. Nakashima, E. Yamashita, and A. Yamaguchi. 2002. Crystal structure of bacterial multidrug efflux transporter AcrB. Nature 419:587-593.
26. National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 5th ed. Approved standard M7-A5. National Committee for Clinical Laboratory Standards, Wayne, Pa.
27. Neyfakh, A. A., V. E. Bidnenko, and L. B. Chen. 1991. Efflux-mediated multidrug resistance in Bacillus subtilis: similarities and dissimilarities with the mammalian system. Proc. Natl. Acad. Sci. USA 88:4781-4785.
28. Neyfakh, A. A., C. M. Borsch, and G. W. Kaatz. 1993. Fluoroquinolone resistance protein NorA of Staphylococcus aureus is a multidrug efflux transporter. Antimicrob. Agents Chemother. 37:128-129.
29. Peck, R. A., J. Hewett, M. W. Harding, Y. M. Wang, P. R. Chaturvedi, A. Bhatnagar, H. Ziessman, F. Atkins, and M. J. Hawkins. 2001. Phase 1 and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin. J. Clin. Oncol. 19:3130-3141.
30. Putman, M., H. W. van Veen, and W. N. Konings. 2000. Molecular properties of bacterial multidrug transporters. Microbiol. Mol. Biol. Rev. 64: 672-693.
31. Renau, T. E., R. Leger, L. Filonova, E. M. Flamme, M. Wang, R. Yen, D. Madsen, D. Griffith, S. Chamberland, M. Dudley, V. Lee, O. Lomovskaya, W. Watkins, T. Ohta, K. Nakayama, and Y. Ishida. 2003. Conformationally-restricted analogues of efflux pump inhibitors that potentiate the activity of levofloxacin in Pseudomonas aeruginosa. Bioorg. Med. Chem. Lett. 13:2755-2758.
32. Renau, T. E., R. Leger, E. Flamme, J. Sangalang, M. W. She, R. Yen, C. L. Gannon, D. Griffith, S. Chamberland, O. Lomovskaya, S. J. Hecker, V. J. Lee, T. Ohta, and K. Nakayama. 1999. Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone levofloxacin. J. Med. Chem. 42:4928-4931.
33. Rowinsky, E. K., L. Smith, Y. M. Wang, P. Chaturvedi, M. Villalona, E. Campbell, C. Aylesworth, S. G. Eckhardt, L. Hammond, M. Kraynak, R. Drengler, J. Stephenson, M. W. Harding, and D. D. von Hoff. 1998. Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. J. Clin. Oncol. 16:2964-2976.
34. Thorarensen, A., A. L. Presley-Bodanar, K. R. Marotti, T. P. Boyle, C. L. Heckaman, M. J. Bohanon, P. K. Tomich, G. E. Zurenko, M. T. Sweeney, and B. H. Yagi. 2001. 3-Arytpiperidines as potentiators of existing antibacterial agents. Bioorg. Med. Chem. Lett. 11:1903-1906.
35. Toppmeyer, D., A. D. Seidman, M. Pollak, C. Russell, K. Tkaczuk, S. Verma, B. Overmoyer, V. Garg, E. Ette, M. W. Harding, and G. D. Demetri. 2002. Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel. Clin. Cancer Res. 8:670-678.
36. Yu, E. W., G. McDermott, H. I. Zgurskaya, H. Nikaido, and D. E. Koshland, Jr. 2003. Structural basis of multiple drug-binding capacity of the AcrB multidrug efflux pump. Science 300:976-980.
37. Zheleznova, E. E., P. N. Markham, A. A. Neyfakh, and R. G. Brennan. 1999. Structural basis of multidrug recognition by BmrR, a transcription activator of a multidrug transporter. Cell 96:353-362.